So a good question.
is have with we the is the up what think the best really we firm FDA us in So have as to in of to considerations interesting as here, well. a It's can of FDA that package we course. and no all There itself. requirement phrase mind ongoing that's to an bring of is
be to as to but the the to well data we ourselves, needs want the them data. we go make the It Phase case best FDA to rapidly as forward as and that bring us X. needs So to can it we possible, can to into robust
is So for currently way the Xb the is it planned from is the exactly we that the planned way arm Phase have this the we Phase running X. we it and of three again arm the three and mirrors the portion have beginning
What to the idea of it's an X. of the to the them feel So go we FDA, to need we mini a Phase magnitude change.
on our five right. are put range a a subjects what bunch the dynamic to from So is of who new readout drug, now baseline imaging of weeks in
they want the than predicting to and bands, readout earlier we better, So know are of what does those clinical look this If like assessments our how getting that that. is big right.
change how are seeing, we So much right.
So we analysis. That's know to our that first of method is part change. very interim sensitive
are a are is patients we in drug. when the on to Now going put they what see themselves change the new
drug think to importantly by that bring half to those have it be significant a that to and the month a who have come FDA XX, maybe time we back We the So had going of to at number about minimum, it's will need scan, of two-thirds right. the baseline XX their think very significant number of gone later a is and subjects subjects a additive a XX, and we week we follow-up. number, scan, be the who least on go to number five will week XX
working say XX not. that, is is, reason at robust weeks XX And clinical as the enough reason that the be can that and the it's weeks where the assessments doctors earlier, drug then mentioned start this I or that important to is for
remember, we but have and then clinical subjects, if the dynamic at the say, wait hey, just we XX range to the XX predicting can how assessment, to right. when herself, are maybe us, eight this of eight as part we or are expect, not XX give can So looking weeks in analysis at we those to this to determinations interim we some XX doctor subjects, week clinical make good start can will his
to think well. as So will important have that be
ongoing. or would But want out be is subjects, least turns would we XX you package XX, accumulate enrolled of FDA subjects are the as It of send ask to months By it that out get bring, trial. couple said, the number to going FDA expect, I we the trial week to subjects at the them was front scans. like several we might time through progressing of are, those comment imagine, week have to half as are So have who we XX like we those so are more in them the when the Patients you we to range. of had the even we on, gong next their that XX in to already. or the
Some XX of scan. scan, had six-month will week them their their have
will the terms is guesses that what expect powering. because in some data which we our dynamic made in our be to modeled design and range educated is that that to of dynamic All can see range additive some of guesstimation, information, X we fundamental the Phase the for
three at, are also thing Jed going begin the for tell And to So as looking we said us, hey, remember, are working? indications, nicely, this main is will we right.
one can of if give reliable readout first working And indicator so early our the not. is, a or the imaging drug doctors is
But If six right it's now, and you also wait didn't one. you work, that months, drug go trial That's error. another trial three all error. to on and
all their You to may and are go healthcare another lives. drugs are anything. they may cost It's joints, six three And up to the with do a go bad, don't stacks system. the getting It year to to bad. things accumulates months. happening it Patients that their all
We rely drug is early say or working can are to have an this not. that readout on to hoping doctors
indications. our our meat of that's main So
all going all clinical same longitudinally. also we points, done, going follow are because robust are for these and having assessments have are that we feel the time are of readout patients a We we we at can imaging imaging to doing
Or is Is months, getting quo? maybe where doctor So are know, that's it several your up payers is things it providers working, getting it's the things one Is readout says, case worse? use months the with patients, So not a hey, to are still this the status doctors, even the want every and home. indication. a to say these every, the to healthcare just three second working? going subjects scans six be indicating followed oh, readout don't says go I The to better? drug
The one is cool. really third
have done macrophages. There three are I thought subtypes RA. RA, involved subtypes over three to three out So it those But before. are of going heavily go right. of quickly. I to are be of Two there this am of
Our targets agent macrophages. imaging
so therapeutic. our And does
subtype does involvement. not The third macrophage heavy have
guys, say, the you imaging really and you And so bad macrophages one of might high subtype involvement for thing right, because you a whole doesn't have well, macrophages. are that's
most if is and country way sites the have subtype opportunity and several reimbursable. there of in unless here. biopsies RA are invasive only around part one and of no It themselves actually currently that that That's you of these might do you out the turns an at unreliable exciting subject, not determining are of what done you, as
or I positively classes that, affected less different by dark without in drugs. the is is So give that have going more you evidence of really There am saying, to is subtype doctor you the drug. some growing the
that look, able low say involvement. those we tell subtype is subject if subject all that there you very scan And class of out has growing low or have to subjects. in this certain work well involved got to the baseline, of can the the something have doctor, other don't evidence has. But able physician the alphas, other macrophage So even at the looks event, in does It our turns be anti-TNF that drugs, any it like macrophage of the think tell at is two. that just two going we a we be even level level the about one even the RA which might
drugs could baseline that rule year might something you scan, class doctor the to am at next I going through I to else. and this say, spend whole the even So that to am give of going going out you
I get maybe right sooner do even a more. drug patients or may year maybe sooner can subjects currently get and And the significantly sooner. to we so mean idea by is to they even And the than be that
are change idea order see give So indications. those FDA weeks. of readout, The an we expect in the the the magnitude of will the baseline data to to are the going of to can the take early we five to us
just way, idea, said, have an told. might I I story We gleaned the will by have what the from this you
groupings As know would yet, we seeing call Those match some to look at -- the signal them but great. be subtype I are subpopulations the I of themselves, don't which might I different, are if groupings baseline scan seeing readout. we wouldn't different the can we
outcome. mentioned. two clinical We that are I on other Phase Xb Two, for things. that know sure that One, to based going study
up seeing our already that lining hypotheses, we great. are which with So is
the of the XX clinical the of to an readout So our magnitude of will early FDA the change week idea order predictive gain assessment. of an ability and
that to got case think, have to already anything support we And to we the our hypotheses. going data make out we turn right the reveal FDA, So data, in these hand need not our am provided to now. I
change are preliminary were definitions We announcing imminently, will based our in data Jed about results the to, will of stretch my home suppose event. really and I soon, and in any on imminent what those statement analyzing said we be I of
